The first and only anti-tissue factor pathway inhibitor (anti-TFPI) has been approved in the EU for the treatment of haemophilia A and B, with Pfizer’s drug gaining marketing ... the standard-of-care ...

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients. With this nod, the once-weekly ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer have lost 13.4% against the industry’s 3.1% growth. The latest decision marks the second EC approval for Pfizer this year ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer this year in the hemophilia space. Earlier in July, the FDA approved Durveqtix (fidanacogene elaparvovec), the ...

The US big pharma company Pfizer ... drug is the first once-weekly, subcutaneous treatment for people with severe hemophilia B, and the first that can be administered via a pre-filled, auto-injector ...

(RTTNews) - Drug major ... treatment of hemophilia A or B. It is also the first hemophilia medicine approved in the EU to be administered via a pre-filled, auto-injector pen. Pfizer said the ...

1 Diagnosed in early childhood, hemophilia inhibits the blood’s ... the FDA at 1-800-FDA-1088. Disclosure notice The information contained in this release is as of November 20, 2024. Pfizer ...

A life-changing drug aimed at reducing onset Alzheimer's has been approved for use in the EU. The treatment is administered intravenously once every fortnight and has been shown in clinical trials ...

RFK Jr.'s potential appointment as Health Secretary could increase scrutiny on Pfizer Inc., impacting drug approvals ... “Make America Healthy Again.” FDA’s war on public health is about ...

On November 15, 2024, the U.S. Food and Drug Administration (FDA) approved revumenib (Revuforj ®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose ...